Search Results - "Maier, Harald Jakob"

Critical Role of RelB Serine 368 for Dimerization and p100 Stabilization by Maier, Harald Jakob, Marienfeld, Ralf, Wirth, Thomas, Baumann, Bernd

“…In mature B cells RelB-containing complexes are constitutively present in the nucleus, and they are less susceptible to inhibitory κB proteins. In most other…”
Get full text

Epithelial NEMO/IKKγ limits fibrosis and promotes regeneration during pancreatitis by Chan, Lap Kwan, Gerstenlauer, Melanie, Konukiewitz, Björn, Steiger, Katja, Weichert, Wilko, Wirth, Thomas, Maier, Harald Jakob

“…Inhibitory κB kinase (IKK)/nuclear factor κB (NF-κB) signalling has been implicated in the pathogenesis of pancreatitis, but its precise function has remained…”
Get more information

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells by Awasthi, Rakesh, Waldron, Edward, Grupp, Stephan, Pulsipher, Michael A., Bader, Peter, Schuster, Stephen J, Maziarz, Richard T, Waller, Edmund K., Jaeger, Ulrich, Thieblemont, Catherine, Dreyling, Martin, Fowler, Nathan, Maier, Harald Jakob, Willert, Jennifer

“…Introduction: Monitoring of chimeric antigen receptor (CAR) transgene levels in peripheral blood post tisagenlecleucel (tisa-cel) infusion provides information…”
Get full text

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis by Shadman, Mazyar, Frigault, Matthew J, Foley, Stephen Ronan, Hill, Brian T., Schofield, Grant, Jacobson, Caron, Jaglowski, Samantha M., Locke, Frederick L., Landsburg, Daniel J., Ram, Ron, Riedell, Peter A, Shah, Gunjan L., Popplewell, Leslie L., Tiwari, Ranjan, Lim, Stephen, Maier, Harald Jakob, Majdan, Marta, Pasquini, Marcelo

“…Background: Richter transformation (RT) is a rare but serious transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most commonly…”
Get full text

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting by Landsburg, Daniel J., Heim, Michael, Moskop, Amy, Foley, Stephen Ronan, Hill, Brian T., Schofield, Grant, Jacobson, Caron, Jaglowski, Samantha M., Locke, Frederick L., Ram, Ron, Riedell, Peter A, Shah, Gunjan L., Popplewell, Leslie L., Tiwari, Ranjan, Lim, Stephen, Maier, Harald Jakob, Majdan, Marta, Pasquini, Marcelo, Frigault, Matthew J

“…Background: Tisagenlecleucel is an autologous CD19-directed chimeric antigen receptor (CAR)-T cell therapy approved for the treatment of patients (pts) with…”
Get full text

Abstract B070: Deletion of NEMO inhibits PanIN development but accelerates PanIN progression towards PDAC by Tsesmelis, Miltiadis, Gerstenlauer, Melanie, Manfras, Uta, Barth, Thomas F.E., Maier, Harald Jakob, Chan, Lap Kwan, Wirth, Thomas

“…Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest types of cancer with a 5-year survival rate of less than 10%. Importantly, the canonical…”
Get full text

Long-Term Durable Responses in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL) Treated with Tisagenlecleucel and Its Association with Persistence of Chimeric Antigen Receptor (CAR) T Cells by Awasthi, Rakesh, Waldron, Edward, Grupp, Stephan A., Pulsipher, Mike A., Bader, Peter, Schuster, Stephen J., Maziarz, Richard T., Waller, Edmund K., Jager, Ulrich, Thieblemont, Catherine, Dreyling, Martin, Fowler, Nathan H., Maier, Harald Jakob, Willert, Jennifer

“…Monitoring CAR transgene level in peripheral blood post tisagenlecleucel (tisa-cel) infusion provides information on CAR-T cell expansion and persistence. To…”
Get full text

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis by Shadman, Mazyar, Frigault, Matthew J., Foley, Stephen Ronan, Hill, Brian T., Schofield, Grant, Jacobson, Caron A., Jaglowski, Samantha, Locke, Frederick L., Landsburg, Daniel J., Ram, Ron, Riedell, Peter A., Shah, Gunjan L., Popplewell, Leslie, Tiwari, Ranjan, Lim, Stephen, Maier, Harald Jakob, Majdan, Marta, Pasquini, Marcelo C.

“…Richter transformation (RT) of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma has an estimated median OS of only 8-12 mo. Tisagenlecleucel…”
Get full text

Durable Efficacy and Manageable Safety in Patients Age ≥75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting by Landsburg, Daniel J., Heim, Michael, Moskop, Amy, Foley, Stephen Ronan, Hill, Brian T., Schofield, Grant, Jacobson, Caron A., Jaglowski, Samantha, Locke, Frederick L., Ram, Ron, Riedell, Peter A., Shah, Gunjan L., Popplewell, Leslie, Tiwari, Ranjan, Lim, Stephen, Maier, Harald Jakob, Majdan, Marta, Pasquini, Marcelo C., Frigault, Matthew J.

“…Tisagenlecleucel is approved for patients (pts) with relapsed/refractory large B-cell lymphoma (r/r LBCL) after ≥2 lines of prior therapy. Previous analysis of…”
Get full text